| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $7.7M | +118.9% |
| SG&A Expense | $17.9M | +134.2% |
| Operating Income | -$34.4M | -207.3% |
| Income Tax | $0 | — |
| Net Income | -$47.3M | -323.8% |
| EPS (Basic) | -$2.74 | -136.2% |
| EPS (Diluted) | -$2.74 | -136.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $8.7M | +109.0% |
| Current Assets | $9.9M | +83.9% |
| Total Assets | $10.1M | +78.2% |
| Current Liabilities | $9.9M | +330.9% |
| Total Liabilities | $10.0M | +299.0% |
| Stockholders' Equity | -$68K | -102.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$22.8M | -122.3% |
| Investing Cash Flow | -$4.6M | — |
| Financing Cash Flow | $31.9M | +151.6% |